Tag: Biotech and Pharma

Direct-to-consumer health-care startup Ro on Wednesday said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly, which aims to streamline access to the popular treatment.

Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk’s Wegovy, in the first head-to-head clinical trial on the weekly injections.

Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic metabolic disease, casting a cloud over the company’s hopes for its first commercial product.

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda.

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key to step in unlocking a big , fast- growing market for its blockbuster franchise 

U.S. government health plans account for the lion’s share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.

Bavarian Nordic A/S announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of 2024.

Εκρηκτική άνοδο 338,6% στα 9,2 εκατ. ευρώ σημείωσαν τα συνολικά κέρδη μετά από φόρους της Lavipharm στο εννεάμηνο του 2024 (από 2,1 εκατ. ευρώ το 2023), λόγω της αναγνώρισης αναβαλλόμενης φορολογικής απαίτησης που προέρχεται από την απόφαση του Ομίλου να θέσει σε εκκαθάριση θυγατρικές εταιρείες οι οποίες στο παρελθόν είχαν σωρεύσει σημαντικές ζημίες.

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.

Merck & Co. Inc.’s stock fell 3% Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to charges stemming from deals with partners Curon Biopharmaceutical and Daiichi Sankyo.

Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide.

Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi.

Moderna’s third-quarter financial results look far better than analysts anticipated, but the beat seems largely to reflect Americans getting their Covid-19 shots earlier this year than they did last year.

Novo Nordisk on Wednesday reported a third-quarter beat on sales of its blockbuster weight-loss drug Wegovy and narrowed its 2024 full-year growth guidance.

Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas’ risks.

Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.

Bristol Myers Squibb on Thursday reported third-quarter earnings and revenue that blew past Wall Street’s expectations thanks to its blockbuster blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth.

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, and slashed its full-year adjusted profit guidance.

Pfizer on Tuesday reported third-quarter revenue and adjusted profit that blew past expectations as the company’s Covid vaccine and antiviral pill Paxlovid helped boost sales.

France is taking a small stake in Sanofi’s consumer healthcare business in order to quell a political backlash, as the pharmaceutical company presses ahead with a €16bn deal that would hand control of the unit to US private equity group Clayton Dubilier & Rice.